Future biologic therapies in asthma;Futuras terapias biológicas en el asma

Archivos de Bronconeumologia

Volumn 50, Issue 8, 2014, Pages 355-361

  Quirce, Santiago ^a   Bobolea, Irina ^a   Domínguez Ortega, Javier ^a   Barranco, Pilar ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Asthma; Biological agents; Monoclonal antibodies; Therapy

Indexed keywords

DULIPUMAB; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 5; LEBRIKIZUMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; UNCLASSIFIED DRUG; ANTI-IGE ANTIBODIES; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; BIOLOGICAL FACTOR; CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIOLOGICAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; HUMAN; MOLECULAR PATHOLOGY; PHARMACODYNAMICS; PHENOTYPE; PRESCRIPTION; SHORT SURVEY; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DESIGN; FORECASTING; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; T LYMPHOCYTE; TRENDS;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL FACTORS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG DESIGN; FORECASTING; HUMANS; IMMUNOGLOBULIN E; INTERLEUKINS; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904515808     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2014.02.002     Document Type: Short Survey

References (56)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO workshop report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute. Updated 2010 [consultado 1 Oct 2013]. Disponible en:. http://www.ginasthma.com/.
2. GEMA (Guía Española del Manejo del Asma). Arch Bronconeumol 2009, 45(Supl 7):1-35.
3. Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012, 21:66-74.
4. Olaguibel J.M., Quirce S., Juliá B., Fernández C., Fortuna A.M., Molina J., et al. Measurement of asthma control according to Global Initiative for Asthma guidelines: A comparison with the Asthma Control Questionnaire. Respir Res 2012, 13:50. MAGIC Study Group.
5. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: The INSPIRE study. BMC Pulm Med 2006, 6:13.
6. Pavord I.D., Wardlaw A.J. The A to E of airway disease. Clin Exp Allergy 2010, 40:62-67.
7. Wenzel S.E. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med 2012, 18:716-725.
8. Lötvall J., Akdis C.A., Bacharier L.B., Bjermer L., Casale T.B., Custovic A., et al. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011, 127:355-360.
9. Tarantini F., Baiardini I., Passalacqua G., Braido F., Canonica G.W. Asthma treatment: 'Magic bullets which seek their own targets'. Allergy 2007, 62:605-610.
10. Gevaert P., Calus L., van Zele T., Blomme K., de Ruyck N., Bauters W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013, 131:110-116.
11. Vennera M.C., Picado C., Mullol J., Alobid I., Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax 2011, 66:824-825.
12. De Llano L.P., Vennera M.C., Álvarez F.J., Medina J.F., Borderías L., Pellicer C., et al. Spanish Registry. Effects of omalizumab in non-atopic asthma: Results from a Spanish multicenter registry. J Asthma 2013, 50:296-301.
13. Garcia G., Magnan A., Chiron R., Contin-Bordes C., Berger P., Taillé C., et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013, 144:411-419.
14. Shiung Y.Y., Chiang C.Y., Chen J.B., Wu P.C., Hung A.F., Lu D.C., et al. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE Fc receptors. Immunobiology 2012, 217:676-683.
15. Smith L.D., Leatherbarrow R.J., Spivey A.C. Development of small molecules to target the IgE: Fc(RI protein-protein interaction in allergies. Future Med Chem 2013, 5:1423-1435.
16. Berair R., Pavord I.D. Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma. Curr Allergy Asthma Resp 2013, 13:469-476.
17. Quirce S., Bobolea I., Barranco P. Emerging drugs for asthma. Expert Opin Emerg Drugs 2012, 17:219-237.
18. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
19. Flood-Page P.T., Menzies-Grow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167:199-204.
20. Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071. International Mepolizumab Study Group.
21. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Eng J Med 2009, 360:985-993.
22. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Eng J Med 2009, 360:973-984.
23. Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-699.
24. Liu Y., Zhang S., Li D.W., Jiang S.J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: A meta-analysis of randomized placebo-controlled trials. PLos One 2013, 8:e59872.
25. Castro M., Mathur s, Hargreave F., Boulet L.P., Xie F., Young J., et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184:1125-1132. Res-5-0010 Study Group.
26. Busse W.W., Katial R., Gossage D., Sari S., Wang B., Kolbeck R., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010, 125:1237-1244.
27. Laviolette M., Gossage D.L., Gauvreau G., Leigh R., Olivenstein R., Katial R., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013, 132:1086-1096.
28. Allakhverdi Z., Allam M., Renzi P.M. Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med 2002, 165:1015-1021.
29. Gauvereau G.M., Boulet L.P., Cockcroft D.W., Baatjes A., Cote J., Deschesnes F., et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952-958.
30. Imakoa H., Campbell H., Babirad I., Watson R.M., Mistry M., Sehmi R., et al. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin Exp Allergy 2011, 41:1740-1746.
31. Gauvereau G.M., Pageau R., Séguin R., Carballo D., Gauthier J., D'anjou H., et al. Dose-response effect of TPI ASM8 in asthmatics after allergen. Allergy 2011, 66:1242-1248.
32. Huang H., Lee C., Chiang B. Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness. Gene Ther 2008, 15:660-667.
33. Oh C.K., Geba G.P., Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010, 19:46-54.
34. Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., al-Mahdi N., Zia-Amirhosseini P., et al. Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002, 130:93-100.
35. PDL Biopharma, Inc. Pilot study in patients with symptomatic steroid-naïve asthma; 2012. [consultado Dic 2011]. Disponible en:. http://clinicaltrials.gov/ct2/show/NCT00024544.
36. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M., et al. Interleukin-4 receptor in moderate atopic asthma A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160:1816-1823.
37. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963-970. IL-4R Asthma Study Group.
38. NIAID. Phase II efficacy study of aerosolized recombinant human IL-4 receptor in asthma; 1999. [consultado Dic 2011]. Disponible en:. http://clinicaltrials.gov/ct2/show/NCT00001909.
39. Gauvreau G.M., Boulet L.P., Cockcroft D.W., Fitzgerald J.M., Carlsten C., Davis B.E., et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011, 183:1007-1014.
40. Wyeth (Pfizer). Study evaluating the effect of IMA-638 in subjects with persistent asthma; 2007. [consultado Feb 2012]. Disponible en:. http://clinicaltrials.gov/ct2/show/NCT00425061.
41. Corren J., Lemanske R.F., Hanania N.A., Korenblast P.E., Parsey M.V., Arron J.R., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
42. Shanafelt A.B., Forte C.P., Kasper J.J., Sanchez-Pescador L., Wetzel M., Gundel R., et al. An immune cell-selective interleukin 4 agonist. Proc Natl Acad Sci U S A 1998, 95:9454-9458.
43. Wenzel S., Wilbraham D., Fuller R., Getz E.B., Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 2007, 370:1422-1431.
44. Aerovance Inc. Press release. Phase 2b clinical trial results show Aerovance's Aerovant™ is effective in patients with eosinophilic asthma: Statistically significant results support novel inhaled IL-4/IL-13 inhibitor's continued clinical development. Bekerley: Aerovance; 2010 [consultado 15 Abr 2012]. Disponible en:. http://www.aerovance.com/news/press-releases/.
45. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013, 368:2455-2466.
46. Parker J.M., Oh C.K., LaForce C., Miller S.D., Pearlman D.S., Le C. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011, 11:14. MEDI-528 Clinical Trials Group.
47. Oh C.K., Leigh R., Mc Laurin K.K., Kim K., Hultquist M., Molfino N.A. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 2013, 14:93.
48. Holgate S.T., Noonan M., Chanez P., Busse W., Dupont L., Pavord I., et al. Efficacy/safety of etanercept in moderate-to-severe asthma: A randomised, controlled trial. Eur Respir J 2011, 37:1352-1359.
49. Erin E.M., Leaker B.R., Nicholson G.C., Tan A.J., Green L.M., Neighbour H., et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006, 174:753-762.
50. Stoll M.L., Solomon D.H., Batra K.L., Simard J.F., Karison E.W., Dellaripa P.F., et al. TNFα inhibitors may improve asthma symptoms: A case series of 12 patients with rheumatoid arthritis and asthma. J Clin Rheumatol 2009, 15:198-200.
51. Taillé C., Poulet C., Marchand-Adam S., Borie R., Dombret M.C., Crestani B., et al. Monoclonal anti-TNF-α antibodies for severe steroid-dependent asthma: A case series. Open Respir Med J 2013, 7:21-25.
52. Brightling C., Berry M., Targeting Amrani Y. TNF-α: A novel therapeutic approach for asthma. J Allergy Clin Immunol 2008, 121:5-10.
53. Wenzel S.E., Barnes P.J., Bleecker E.R., Bousquet J., Busse W., Dahlén S.E., et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558.
54. Busse W.W., Israel E., Nelson H.S., Baker J.W., Charous B.L., Young D.Y., et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma. Am J Respir Crit Care Med 2008, 178:1002-1008.
55. Kon O.M., Sihra B.S., Loh L.C., Barkans J., Compton C.H., Bernes N.C., et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4zT-cells in asthma. Eur Respir J 2001, 18:45-52.
56. Caruso M., Crisafulli E., Lizzio R., Polosa R. Biologic therapy for atopic asthma and beyond. Curr Opin Allergy Clin Immunol 2013, 13:677-685.